Neuroblastoma stage 4S: a multifocal stem-cell disease of the developing neural crest

Max M van Noesel

doi:10.1016/S1470-2045(12)70012-8

Neuroblastoma stage 4S: a multifocal stem-cell disease of the developing neural crest

Onderzoeksoutput: Bijdrage aan tijdschrift › Artikel › peer review

23 Citaten (Scopus)

Originele taal-2	Engels
Pagina's (van-tot)	229-30
Aantal pagina's	2
Tijdschrift	The Lancet Oncology
Volume	13
Nummer van het tijdschrift	3
DOI's	https://doi.org/10.1016/S1470-2045(12)70012-8
Status	Gepubliceerd - mrt. 2012
Extern gepubliceerd	Ja

Toegang tot document

10.1016/S1470-2045(12)70012-8

Citeer dit

@article{690130bd2e17469fbad32bb90043676d,

title = "Neuroblastoma stage 4S: a multifocal stem-cell disease of the developing neural crest",

keywords = "Adrenal Gland Neoplasms/genetics, Animals, Bone Marrow Neoplasms/genetics, Cell Movement, Gene Expression Regulation, Neoplastic, Humans, Liver Neoplasms/genetics, Neoplasm Invasiveness, Neoplasm Staging, Neoplastic Stem Cells/pathology, Neural Crest/pathology, Neuroblastoma/genetics, Prognosis, Skin Neoplasms/genetics",

author = "{van Noesel}, {Max M}",

year = "2012",

month = mar,

doi = "10.1016/S1470-2045(12)70012-8",

language = "English",

volume = "13",

pages = "229--30",

journal = "The Lancet Oncology",

issn = "1474-5488",

publisher = "Elsevier Ltd.",

number = "3",

}

TY - JOUR

T1 - Neuroblastoma stage 4S

T2 - a multifocal stem-cell disease of the developing neural crest

AU - van Noesel, Max M

PY - 2012/3

Y1 - 2012/3

KW - Adrenal Gland Neoplasms/genetics

KW - Animals

KW - Bone Marrow Neoplasms/genetics

KW - Cell Movement

KW - Gene Expression Regulation, Neoplastic

KW - Humans

KW - Liver Neoplasms/genetics

KW - Neoplasm Invasiveness

KW - Neoplasm Staging

KW - Neoplastic Stem Cells/pathology

KW - Neural Crest/pathology

KW - Neuroblastoma/genetics

KW - Prognosis

KW - Skin Neoplasms/genetics

U2 - 10.1016/S1470-2045(12)70012-8

DO - 10.1016/S1470-2045(12)70012-8

M3 - Article

C2 - 22381931

SN - 1474-5488

VL - 13

SP - 229

EP - 230

JO - The Lancet Oncology

JF - The Lancet Oncology

IS - 3

ER -